Consulta: creatorFacets:"Vigani,Aline Gonzalez"
Registros recuperados: 4
Data/hora: 06/06/2024 10:43:27

Hepatitis B virus surface antigen seroconversion in HIV-infected individual after pegylated interferon-alpha treatment: a case report
Provedor de dados: 80
Autores: Delicio,Adriane Maira; Abati,Paulo Afonso Martins; Vigani,Aline Gonzalez.
Hepatitis B virus (HBV) infects from 6 to 14% of HIV-infected individuals. Concurrent HIV/HBV infection occurs due to the overlapping routes of transmission, particularly sexual and parenteral. HIV-infected patients that have acute hepatitis B have six times greater risk of developing chronic hepatitis B, with higher viral replication, rapid progression to end-stage liver disease and shorter survival. The coinfection is also associated with poor response to hepatitis B treatment with interferon-alpha and increased liver toxicity to the antiretroviral therapy. Herein, we describe the case of a 35-year-old man who engages in sex with men and presented with newly diagnosed HIV-1, serological markers for acute hepatitis B and progression to chronic hepatitis B...
Tipo: Info:eu-repo/semantics/report
Palavras-chave: HIV; Hepatitis B; HBsAg; Peginterferon.
Ano: 2013
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1678-91992013000100503

Therapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
Provedor de dados: 55
Autores: Vigani,Aline Gonzalez; Gonçales,Eduardo Sellan; Pavan,Maria Helena Postal; Genari,Flavia; Tozzo,Raquel; Lazarini,Maria Silvia Kroll; Fais,Viviane; Feltrin,Adriana; Gonçales,Neiva Sellan; Gonçales Jr,Fernando Lopes.
BACKGROUND: Pegylated interferon (Peg-IFN) and standard interferon (IFN) play a significant role in the treatment of hepatitis C virus (HCV) infection. Biosimilar standard IFN is widely available in Brazil for the treatment of HCV infection genotypes 2 or 3, but its efficacy compared to Peg-IFN is unknown. OBJECTIVE: To compare the sustained virological response (SVR) rates following treatment with biosimilar standard IFN plus ribavirin (RBV) versus Peg-IFN plus RBV in patients with HCV genotypes 2 or 3 infection. METHODS: A retrospective cohort study was conducted in patients with HCV genotypes 2 or 3 infection treated with biosimilar standard IFN plus RBV or with Peg-IFN plus RBV. SVR rates of the two treatments were compared. RESULTS: From January 2005...
Tipo: Info:eu-repo/semantics/article
Palavras-chave: Interferons; Hepatitis C; Treatment outcome.
Ano: 2012
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702012000300003

Extended treatment with interferon and ribavirin in a hemodialysis patient with chronic hepatitis C
Provedor de dados: 55
Autores: Vigani,Aline Gonzalez; Pavan,Maria HP; Tozzo,Raquel; Gonçales,Eduardo SL; Lazarini,Maria SK; Oliveira,Alexandre Macedo de; Gonçales Jr,Fernando L.
Hemodialysis patient with chronic HCV infection,who was started on monotherapy with interferon.Qualitative HCV RNA remained positive at 12 weeks of treatment; ribavirin was associated. HCV RNA was negative at week 24 and treatment was extended to 72 weeks. HCV RNA negative six months after treatment.
Tipo: Info:eu-repo/semantics/report
Palavras-chave: Hepatitis C virus; Hemodialysis; Treatment; Interferon; Ribavirin.
Ano: 2010
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702010000200016

Adverse event management
Provedor de dados: 55
Autores: Vigani,Aline Gonzalez.
Tipo: Info:eu-repo/semantics/other
Ano: 2007
URL: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702007000700020